Angelos Stergiou’s team, head to Sellas Life Sciences and keep an eye on happenings around the website.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Vice Chairman of SELLAS Life Sciences
Dr. Angelos M. Stergiou, MD is the Founder, Chief Executive Officer and Vice Chairman of SELLAS Life Sciences Group. Angelos M. Stergiou and his company are changing medicine and science as we know it, and in doing so, they’re potentially saving countless lives.
As the WT1 cancer vaccine trials gain momentum and exposure, Dr. Angelos M. Stergiou and his team are receiving media attention and international acclaim.
The points mentioned on next slide is just scratch the surface of this fascinating company that’s pioneering the field of cancer vaccination:
Company Overview. SELLAS Life Sciences Group is a biopharmaceutical company that was founded in 2012 by Dr. Stergiou and his colleague, Dr. Miltos K. Sugiultzoglu, MD. It is centered around developing novel cancer therapeutics to save lives and to push cancer vaccination to the next level.
When speaking about the company, Dr. Stergiou was quoted in a 2016 interview stating: “I have always wanted to give back to humanity, and without clinical research, discovery and drug development, we would not have new drugs. The biotechnology sector is a passion of mine. It combines medicine, research and business, and I truly love doing every day.” He continued, saying: “The fact that we are currently developing a cancer vaccine with Memorial Sloan Kettering Cancer Center is very exciting and gets me going.”
WT1 Cancer Vaccine. The WT1 cancer vaccine is the most promising oncology product within SELLAS Life Sciences Group. It is named for the WT1 antigen, found in many cancers and few healthy adult cells. It teaches the immune system to seek and destroy the antigen, creating an effective internal response against cancer and recurring tumors. It is among Dr. Stergiou’s biggest accomplishments.
In a recent interview, he stated “We are entering pivotal Phase 3 studies [for the WT1 cancer vaccine] and have an exciting path ahead of us.” In further discussions about the WT1 cancer vaccine, Dr. Stergiou was quoted saying “The thirst to get to the finish line and get [the WT1 cancer vaccine] approved, so we can potentially save lives, is breathtaking.”
To follow the progression of SELLAS Life Sciences Group and Dr. Angelos M. Stergiou’s team, head to www.sellaslifesciences.com and keep an eye on happenings around the website. Alternately, stay current with oncology news and you’re sure to see breakthrough trials in the near future.
Also visit here: